Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuts health claim OK’ed

This article was originally published in The Tan Sheet

Executive Summary

FDA affirms first qualified health claim under "Interim Evidence-Based Ranking System for Scientific Data" guidance published in July 11 Federal Register (1"The Tan Sheet" July 14, 2003, p. 3). The claim will allow manufacturers of peanuts, almonds, walnuts and other nuts to say that "scientific evidence suggests but does not prove" that eating 1.5 oz in conjunction with a diet low in saturated fat and cholesterol "may" reduce the risk of developing heart disease...

You may also be interested in...



Qualified Health Claims Scientific Evidence To Be Assessed, Ranked By FDA

FDA will rank qualified health claims for use on dietary supplement and food products based on an evaluation of the scientific evidence that supports them, according to guidelines announced July 10

Regulatory Measures Could Mitigate Coronavirus Risks In Europe

As part of its response to the coronavirus outbreak, the European association representing generic and biosimilar drug companies, Medicines for Europe, has set out a series of policy recommendations that it says could help to mitigate the possible risks to medicines supply.

Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches

Scrip's Brian Yang describes what life is like in China as the authorities battle to contain the coronavirus, and drug developers race to find vaccine and anti-virals against the new threat. Plus news on Novartis' bold initiative with England on inclisiran, and what lies ahead for Biogen and Alzheimer's treatment in 2020

Topics

UsernamePublicRestriction

Register

PS095719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel